Gentian Diagnostics ASA

DB:6FK Stock Report

Market Cap: €54.6m

Gentian Diagnostics Valuation

Is 6FK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6FK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6FK (€3.48) is trading above our estimate of fair value (€3.29)

Significantly Below Fair Value: 6FK is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6FK?

Key metric: As 6FK is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6FK. This is calculated by dividing 6FK's market cap by their current revenue.
What is 6FK's PS Ratio?
PS Ratio4.1x
SalesNOK 154.12m
Market CapNOK 629.23m

Price to Sales Ratio vs Peers

How does 6FK's PS Ratio compare to its peers?

The above table shows the PS ratio for 6FK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
PHH2 Paul Hartmann
0.3xn/a€760.1m
PUS PULSION Medical Systems
3.8xn/a€134.4m
AAQ1 aap Implantate
1.9xn/a€22.4m
M3V MeVis Medical Solutions
2.6xn/a€45.9m
6FK Gentian Diagnostics
4.1x25.7%€629.2m

Price-To-Sales vs Peers: 6FK is expensive based on its Price-To-Sales Ratio (4.1x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does 6FK's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$827.50m
PHH2 Paul Hartmann
0.3xn/aUS$791.49m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
6FK 4.1xIndustry Avg. 3.5xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6FK is expensive based on its Price-To-Sales Ratio (4.1x) compared to the European Medical Equipment industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is 6FK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6FK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.1x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: 6FK is expensive based on its Price-To-Sales Ratio (4.1x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.0%

1Y

-38.8%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.1%

1Y

16.0%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%